匹多莫德联合长期氧疗治疗慢性阻塞性肺疾病稳定期的效果观察.docVIP

匹多莫德联合长期氧疗治疗慢性阻塞性肺疾病稳定期的效果观察 　　【摘要】目的观察匹多莫德联合长期氧疗(LTOT)治疗慢性阻塞性肺疾病(COPD)稳定期的效果。方法27例有长期吸氧指征的COPD稳定期患者在常规治疗基础上予以匹多莫德800 mg, 1次/d, 共60 d ；每日家庭氧疗, 共1年。治疗前后行身高、体质量、肺功能、6分钟步行距离(6MWD)检测；填写改良版英国医学研究委员会呼吸困难问卷(MMRC)；计算BODE指数。结果治疗1年后患者BODE指数、MMRC分级均明显下降(P0.01)；FEV1占预计值%、6MWD明显增加(P0.05)；开始治疗后1年内急性加重发作次数明显少于治疗前(P0.01)；未见明显药物不良反应。结论匹多莫德联合LTOT治疗COPD稳定期可减轻患者症状、改善肺功能、提高生活质量、减少急性加重的发作次数。 　　【关键词】慢性阻塞性肺疾病；匹多莫德；长期氧疗 　　 　　Effect observation on pidotimod combined with long-term oxygen therapy in the treatment of stable chronic obstructive pulmonary disease TANG Fu-xiao. Dongcai Hospital of Youxian District, Mianyang 621000, China 　　【Abstract】Objective#8195;To investigate the effect of pidotimod combined with long-term oxygen therapy(LTOT) in the treatment of stable chronic obstructive pulmonary disease(COPD).Methods#8195;On the basis of conventional therapy, 27 cases of COPD Patients with long term oxygen therapy indications by oral administration of pidotimod 800 mg, once a day for 60 d; daily home oxygen therapy for a year. Before and after treatment, measured the height, weight, 6 minutes walking distance (6MWD); examined the pulmonary function; filled in the improved version of the breathlessness measurement using the modified British Medical Research Council (MMRC); calculated the BODE index. Results#8195;After 1 year of treatment, the BODE index and MMRC classification were decreased than before (P0.01); FEV1 percentage of predicted value, 6 MWD increased significantly (P0.05); times of acute exacerbation within 1 year than before treatment significantly reduced (P0.01); there was no obvious drug adverse reaction. Conclusion#8195;Pidotimod combined with LTOT in the treatment of stable COPD, can alleviate the symptoms, improve lung function and quality of life and reduce the number of episodes of acute exacerbation. 　　【Key words】Chronic obstructive pulmonary disease; Pidotimod; Long-term oxygen therapy慢性阻塞性肺疾病(chronic obstructive pulmonary disease, COPD)是一种常见病及多发病, 严重影响劳动力及